Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2000-05-15 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Ad hoc-Service: EVOTEC BioSystems AG 2. Meldu
Regulatory Filings Classification · 100% confidence The document is titled 'Ad hoc-Service' and is dated May 15, 2000. It announces a significant technological breakthrough ('technologischen Quantensprung') regarding a new method for testing membrane-bound proteins (GPCRs) relevant to the pharmaceutical industry. The content is a press release detailing scientific progress and its implications for the company's business, rather than a formal regulatory filing like a 10-K, an earnings report (ER), or a detailed management discussion (MDA). Since it is a general, time-sensitive announcement of corporate news that doesn't fit the specific categories like DIV, CAP, or DIRS, it falls best under the general regulatory announcement category, RNS, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but the focus here is on a technology update. Given the nature of an 'Ad hoc-Mitteilung' (Ad hoc announcement) detailing operational/scientific news, RNS (Regulatory Filings/General Announcement) is the most appropriate general classification, as it is not a formal financial report or a specific corporate action notice.
2000-05-15 German
Ad hoc-Service: EVOTEC BioSystems AG English
Earnings Release Classification · 100% confidence The document is explicitly titled "First Quarter Report 2000" and contains detailed financial metrics for the first quarter (revenue, operating loss, deficit) along with operational updates and future outlook. This content structure is characteristic of a comprehensive periodic financial report covering a period shorter than a full year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an Earnings Release (ER) as it provides substantial detail beyond key highlights, nor is it a full Annual Report (10-K). Q1 2000
2000-05-15 English
Ad hoc-Service: EVOTEC BioSystems AG Deutsch
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung' (Ad hoc announcement) and is dated May 15, 2000. It explicitly reports on the 'Bericht über das erste Quartal 2000' (Report on the first quarter 2000), detailing revenue increases, operating loss, personnel changes, technological progress, and plans for a stock split. This content—a summary of key financial and operational highlights for a specific reporting period (Q1 2000)—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR), nor is it a transcript (CT) or a presentation (IP). Since it announces the results for a period shorter than a year, it is classified as an Earnings Release (ER). Q1 2000
2000-05-15 German
Ad hoc-Service: EVOTEC BioSystems AG english
Earnings Release Classification · 100% confidence The document is an 'Ad hoc-announcement' dated April 4, 2000, summarizing the financial performance for the fiscal year 1999. It details revenue increases, operating results, net income compared to analyst expectations, cash flow improvements, and provides a forward-looking statement for 2000. This content structure—a summary of annual performance released shortly after the fiscal year end, often preceding the full 10-K—is characteristic of an Earnings Release (ER). While it covers the full year, it is presented as a news announcement highlighting key figures rather than the comprehensive, audited filing (10-K) or a detailed management discussion (MDA). Given the focus on key results and outlook, ER is the most appropriate classification, although it covers an annual period. FY 1999
2000-04-04 English
Ad hoc-Service: EVOTEC BioSystems AG dt./engl
Regulatory Filings Classification · 95% confidence The document is an 'Ad hoc-Mitteilung' (Ad hoc announcement) dated March 2, 2000, detailing a new drug discovery alliance between EVOTEC BioSystems AG and SUGEN Inc. This type of announcement, which details a significant business development, partnership, or contract, typically falls under general regulatory announcements or capital/financing updates if it involves significant financial terms. Since it describes a strategic alliance involving service fees, milestone payments, and future royalties, it is a significant corporate event. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the nature of announcing a major strategic partnership and contract, it fits best under a general regulatory announcement category, as it is a material event disclosure. 'Regulatory Filings' (RNS) is the most appropriate fallback for material, non-standardized corporate disclosures that aren't explicitly covered by other codes like M&A (TAR) or Capital Changes (CAP). The document length (4648 chars) is short enough that it could potentially be an RPA, but it contains the full substance of the announcement rather than just stating a report is attached. Therefore, RNS is the best fit for this material, ad-hoc corporate event disclosure.
2000-03-02 German
Ad hoc-Service: EVOTEC BioSystems AG dt./engl
Capital/Financing Update Classification · 95% confidence The document is an 'Ad hoc-Mitteilung' (Ad hoc announcement) dated January 19, 2000, detailing a strategic alliance between EVOTEC BioSystems AG and Trega Biosciences, Inc. It describes a collaboration on drug discovery, licensing of software (IDEA), and the purchase of a substance library (Chem.Folio). This type of announcement, which details a significant business transaction or partnership outside of routine financial reporting (like 10-K or ER), fits best under the general category of significant corporate actions or regulatory disclosures. Since it is not a standard financial report (10-K, IR, ER, MRQ), nor a management change (MANG), nor a capital event (CAP, SHA), nor a shareholder vote result (DVA), it is best classified as a general regulatory announcement or a filing that doesn't fit a specific financial report type. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a non-standard, material business announcement, although 'M&A Activity' (TAR) might be considered if the collaboration was a merger, which it is not (it's a strategic alliance/licensing deal). Since it is a direct, immediate announcement of a material event, RNS is the best fit among the provided codes for a non-standard disclosure.
2000-01-19 German

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.